Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.
about
Staphylococcus aureus and Lipopolysaccharide Modulate Gene Expressions of Drug Transporters in Mouse Mammary Epithelial Cells Correlation to Inflammatory BiomarkersExpression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV preventionIndoxyl sulfate down-regulates SLCO4C1 transporter through up-regulation of GATA3.Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expressionHIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug DispositionImpact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil.Nitric oxide and interleukin-1β stimulate the proteasome-independent degradation of the retinoic acid hydroxylase CYP2C22 in primary rat hepatocytes.Hepatic cytochrome P450s, phase II enzymes and nuclear receptors are downregulated in a Th2 environment during Schistosoma mansoni infection.Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in miceGeriatric conditions and the risk of adverse drug reactions in older adults: a review.Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Inflammation and pharmacokinetics: potential implications for HIV-infection.Effect of Liver Disease on Hepatic Transporter Expression and Function.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.Effects of Low-Dose Escherichia coli Lipopolysaccharide-Induced Endotoxemia on Morphine Pharmacokinetics in an Animal Model.Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats.Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation.Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs.Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
P2860
Q28553833-CE7534CD-0605-45E9-AE5E-B8574EF23862Q33769971-DD6AA814-544C-47BD-B384-27ECF17E0900Q34846428-645A96C2-6DB2-46E2-98F6-E4F29343CBB5Q35317533-DD5D5704-2E89-4C41-BF35-B3C04EF9512AQ36888037-53F355D6-FAF0-49DB-9EAE-9178BBD87746Q37335874-C2E46B77-0A3C-4A22-A15D-52C44BEC1DE6Q37405346-3BF491DD-97EA-42CC-99AC-9423AB29E2B5Q37422679-5FB0D006-B067-421B-8538-63E3DAB849BEQ37663380-E3722B5F-D4D5-4CED-89D3-8DA4CCF6762AQ38085224-4986CC61-FC98-46C0-9521-A67CBCD9D380Q38166454-FC7E70C2-CC0E-40B6-8E45-21E01757DAA8Q38390695-7B4D01FC-4904-4CC9-BF29-BD684BE02479Q38644392-33C7B279-8269-47BC-BD93-7C095F72DEC1Q38704025-06014ECA-688A-41B9-99B8-42B0022E5F34Q38740792-B38AF159-32C0-4D58-9212-55680ACCE4BDQ38808182-24F8B312-C512-4CC8-9092-ABA42746188DQ38937177-CC1CC6AE-CE45-4838-B3E2-4FB8E6DA2E98Q40057969-45EED0BD-F116-4496-BB43-4F4155DDF94CQ40755393-9855297D-56AD-4939-83FF-6538791E659BQ40956659-C9531FA3-BD0D-47E2-9F7D-AEAC105AE5B9Q46016007-3948EBA3-3C37-46A1-87E7-1C5C81EABE1BQ47847406-589E481A-3FFB-4629-97F4-3FE6D1BEED31Q50074569-B436297C-5F7A-4FCF-A734-D8BC189E2C6BQ55280979-C29D9197-29B0-49FB-80D4-F362469A9798Q58584090-C256F62A-235F-4EFA-AFAB-06E2A01AB248
P2860
Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inflammation-mediated changes ...... for therapeutic drug response.
@en
Inflammation-mediated changes ...... for therapeutic drug response.
@nl
type
label
Inflammation-mediated changes ...... for therapeutic drug response.
@en
Inflammation-mediated changes ...... for therapeutic drug response.
@nl
prefLabel
Inflammation-mediated changes ...... for therapeutic drug response.
@en
Inflammation-mediated changes ...... for therapeutic drug response.
@nl
P2093
P2860
P356
P1476
Inflammation-mediated changes ...... for therapeutic drug response.
@en
P2093
Alexander M Cressman
Micheline Piquette-Miller
Vanja Petrovic
P2860
P356
10.1586/ECP.11.66
P407
P577
2012-01-01T00:00:00Z